Ibuzatrelvir

An antiviral medication used in the treatment of COVID-19

Ibuzatrelvir is an antiviral drug that has been developed for the treatment of COVID-19, the disease caused by the SARS-CoV-2 virus. It is designed to inhibit the replication of the virus within the host cells, thereby reducing the severity and duration of the illness.

Mechanism of Action

Ibuzatrelvir functions by targeting a specific enzyme known as the RNA-dependent RNA polymerase (RdRp) of the SARS-CoV-2 virus. This enzyme is crucial for the replication of the viral RNA genome. By inhibiting RdRp, Ibuzatrelvir effectively halts the replication process, preventing the virus from multiplying and spreading within the host.

Pharmacokinetics

Ibuzatrelvir is administered orally and is absorbed through the gastrointestinal tract. The drug is metabolized in the liver and has a half-life that allows for once-daily dosing. It is primarily excreted through the kidneys.

Clinical Trials

Clinical trials have demonstrated that Ibuzatrelvir is effective in reducing viral load in patients with mild to moderate COVID-19. The trials also showed a reduction in the duration of symptoms and a decrease in the progression to severe disease.

Side Effects

Common side effects of Ibuzatrelvir include headache, nausea, and fatigue. Serious side effects are rare but may include liver enzyme abnormalities and allergic reactions.

Regulatory Status

Ibuzatrelvir has been granted emergency use authorization in several countries and is under review for full approval by regulatory agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Also see

• Antiviral drug
• COVID-19 pandemic
• SARS-CoV-2
• RNA-dependent RNA polymerase
• Drug development

Template:COVID-19 drugs Drugs for HIV Infection, in the Subclass Antiretroviral Agents

• Fusion Inhibitors (HIV)
  • Enfuvirtide, Maraviroc

• Integrase Inhibitors (HIV)
  • Dolutegravir, Elvitegravir, Raltegravir

• Monoclonal Antibodies
  • Ibalizumab

• Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
  • Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine

• Nucleoside Analogues (HIV)
  • Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, Zidovudine

• Protease Inhibitors (HIV)
  • Amprenavir, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir

Drugs for Hepatitis B

• Alpha Interferon, Adefovir, Emtricitabine, Entecavir, Lamivudine, Telbivudine, Tenofovir

Drugs for Hepatitis C

• Interferon Based Therapies
  • Alpha Interferon and Peginterferon, Ribavirin

HCV NS5A Inhibitors

• Daclatasvir, Elbasvir, Ledipasvir, Ombitasvir, Pibrentasvir, Velpatasvir

HCV NS5B Inhibitors (Polymerase inhibitors)

• Dasabuvir, Sofosbuvir

HCV Protease Inhibitors

• Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir

Combination Therapies

• Epclusa, Harvoni, Mavyret, Technive, Viekira Pak, Vosevi, Zepatier

Drugs for Herpes Virus

• infections (HSV), CMV, others

Acyclovir, Cidofovir, Famciclovir, Foscarnet, Ganciclovir, Valacyclovir, Valganciclovir

Drugs for Influenza

• Amantadine, Oseltamivir, Peramivir, Rimantadine, Zanamivir